Although the development of modern molecular biology disciplines, such as genomics, proteomics, and bioinformatics, has brought great strides to drug R&D theory, new drug development has not escaped empirical nature due to the complexity of the biochemical reactions that drug molecules undergo in humans. Traditional drug research and development is dominated by medicinal chemistry experts, who typically empirically conduct drug screens for every 5,000 to 1,0000 compounds proposed, with only one compound ultimately eligible for clinical testing and eventual marketing. A new drug takes more than 10 years and costs nearly $2.6 billion from development to approval to the market, with a clinical success rate of less than 10% . The long R&D cycle, high R&D cost and low success rate have become three huge barriers to the development of new drugs .